BTC
ETH
HTX
SOL
BNB
View Market
简中
繁中
English
日本語
한국어
ภาษาไทย
Tiếng Việt

ALT5 Sigma CEO: The company holds approximately 7.3 billion WLFI tokens, worth nearly $1 billion.

2025-12-18 13:50

According to Odaily Planet Daily, in a letter to shareholders, Tony Isaac, CEO of ALT5 Sigma Corporation (ALT5), stated that the company has built a payment infrastructure that is undervalued by the market, processing over $5 billion in digital asset transactions and serving corporate and institutional clients across multiple jurisdictions. The ALT5 Pay and ALT5 Prime platforms are real-time operating systems that process cryptocurrency-to-fiat settlements, card issuance, and institutional transactions daily.

Isaac stated that AlphaTON Capital and PagoPay's selection of ALT5's infrastructure for their Mastercard crypto spending program validates the value of the company's technological and business partnership. As AlphaTON develops payment applications within the TON ecosystem, ALT5's infrastructure will support applications with enormous potential scale.

ALT5 is exploring integrating World Liberty Financial Inc.'s USD1 stablecoin (with a total supply exceeding $2.7 billion) into its payments platform. ALT5 holds approximately 7.3 billion WLFI tokens, worth about $1 billion at current prices. The company plans to strategically deploy these assets to generate revenue and increase the number of tokens per share over time while developing its core payments business.

Isaac pointed out that there is a significant gap between ALT5's current market capitalization ($155.5 million) and the value reflected on its balance sheet, and the market's valuation of the company's WLFI token holdings is far below their potential value. The company will narrow this valuation gap through a comprehensive strategy including strengthening financial reporting processes, achieving business growth, optimizing WLFI holding returns, and transparent communication.

ALT5's traditional biotechnology business, Alyea Therapeutics, is advancing clinical trials for non-addictive pain treatments, and the company will evaluate its strategic optimization options. (businesswire)